- Home
- INCY vs SNN Comparison
INCY vs SNN Comparison
Compare INCY & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INCY | SNN |
|---|---|---|
| Founded | 1991 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 14.0B |
| IPO Year | 1993 | 1999 |
Fundamental Metrics
Financial Performance| Metric | INCY | SNN |
|---|---|---|
| Price | $101.16 | $32.94 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 20 | 4 |
| Target Price | ★ $90.71 | $32.83 |
| AVG Volume (30 Days) | ★ 2.1M | 579.1K |
| Earning Date | 10-28-2025 | 03-02-2026 |
| Dividend Yield | N/A | ★ 2.25% |
| EPS Growth | ★ 3878.02 | 59.91 |
| EPS | ★ 5.90 | 0.56 |
| Revenue | $4,813,105,000.00 | ★ $5,944,000,000.00 |
| Revenue This Year | $19.33 | $7.85 |
| Revenue Next Year | $10.47 | $5.43 |
| P/E Ratio | ★ $17.17 | $58.15 |
| Revenue Growth | ★ 18.09 | 5.35 |
| 52 Week Low | $53.56 | $23.69 |
| 52 Week High | $109.28 | $38.79 |
Technical Indicators
Market Signals| Indicator | INCY | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 51.09 | 42.51 |
| Support Level | $100.55 | $32.34 |
| Resistance Level | $107.61 | $33.56 |
| Average True Range (ATR) | 2.78 | 0.39 |
| MACD | -1.01 | 0.09 |
| Stochastic Oscillator | 11.46 | 62.11 |
Price Performance
Historical ComparisonAbout INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.